Prentiss Smith & Co. Inc. Lowers Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Prentiss Smith & Co. Inc. trimmed its position in REGENXBIO Inc. (NASDAQ:RGNX) by 10.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,107 shares of the biotechnology company’s stock after selling 1,133 shares during the period. Prentiss Smith & Co. Inc.’s holdings in REGENXBIO were worth $181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RGNX. Harbor Capital Advisors Inc. grew its position in REGENXBIO by 10.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 48,559 shares of the biotechnology company’s stock valued at $799,000 after buying an additional 4,453 shares during the last quarter. Raymond James & Associates lifted its holdings in REGENXBIO by 405.3% in the third quarter. Raymond James & Associates now owns 100,620 shares of the biotechnology company’s stock valued at $1,656,000 after acquiring an additional 80,706 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in REGENXBIO by 77.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 114,962 shares of the biotechnology company’s stock valued at $1,892,000 after acquiring an additional 50,056 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in REGENXBIO by 47.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,540 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 3,379 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in REGENXBIO by 8.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 208,307 shares of the biotechnology company’s stock valued at $3,429,000 after acquiring an additional 15,794 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Trading Up 0.1 %

Shares of NASDAQ:RGNX traded up $0.02 during midday trading on Thursday, hitting $16.06. 604,238 shares of the stock were exchanged, compared to its average volume of 719,818. The stock has a market cap of $787.58 million, a P/E ratio of -2.66 and a beta of 1.29. REGENXBIO Inc. has a twelve month low of $11.83 and a twelve month high of $28.80. The company has a 50 day moving average price of $19.97 and a 200-day moving average price of $17.85.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.16). REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The firm had revenue of $22.30 million during the quarter, compared to analyst estimates of $34.01 million. During the same period in the previous year, the firm posted ($1.38) EPS. The company’s revenue for the quarter was down 28.8% compared to the same quarter last year. On average, equities research analysts expect that REGENXBIO Inc. will post -3.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RGNX shares. SVB Leerink raised REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 target price for the company in a report on Wednesday, March 6th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 7th. Stifel Nicolaus reissued a “buy” rating and issued a $40.00 target price on shares of REGENXBIO in a report on Friday, April 12th. Robert W. Baird raised their target price on REGENXBIO from $34.00 to $39.00 and gave the company an “outperform” rating in a report on Wednesday, March 6th. Finally, Leerink Partnrs raised REGENXBIO from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $38.45.

Insider Activity at REGENXBIO

In related news, CEO Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $16.76, for a total value of $251,400.00. Following the completion of the transaction, the chief executive officer now owns 408,035 shares of the company’s stock, valued at approximately $6,838,666.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other REGENXBIO news, insider Steve Pakola sold 12,878 shares of REGENXBIO stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the sale, the insider now owns 107,192 shares in the company, valued at approximately $3,039,965.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $16.76, for a total value of $251,400.00. Following the completion of the sale, the chief executive officer now owns 408,035 shares of the company’s stock, valued at approximately $6,838,666.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,878 shares of company stock valued at $1,217,370. 13.13% of the stock is owned by insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.